ReP USP - Resultado da busca

Artigo de periodico
Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio (2020)
Pippa, Leandro Francisco ; Oliveira, Milena Locci de ; Rocha, Adriana; Andrade, Jurandyr Moreira de ; Lanchote, Vera Lucia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: ANTINEOPLÁSICOS, FARMACOCINÉTICA, VARIAÇÃO (BIOLOGIA), NEOPLASIAS MAMÁRIAS, MIOCARDIOPATIA CONGESTIVA, QUIMIOTERAPIA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIPPA, Leandro Francisco; OLIVEIRA, Milena Locci de; ROCHA, Adriana; ANDRADE, Jurandyr Moreira de; LANCHOTE, Vera Lucia. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis, Amsterdam, v. 185, 2020. Disponível em: < https://doi.org/10.1016/j.jpba.2020.113231 > DOI: 10.1016/j.jpba.2020.113231.
APA
Pippa, L. F., Oliveira, M. L. de, Rocha, A., Andrade, J. M. de, & Lanchote, V. L. (2020). Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis, 185. doi:10.1016/j.jpba.2020.113231
NLM
Pippa LF, Oliveira ML de, Rocha A, Andrade JM de, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185Available from: https://doi.org/10.1016/j.jpba.2020.113231
Vancouver
Pippa LF, Oliveira ML de, Rocha A, Andrade JM de, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185Available from: https://doi.org/10.1016/j.jpba.2020.113231
Artigo de periodico
Analysis of the relationship between hospital characteristics and survival in ovarian cancer: A historical cohort (2020)
Moterani, Vinicius Cesar; Tiezzi, Daniel Guimarães ; Andrade, Jurandyr Moreira de ; Reis, Francisco José Cândido dos
Source: Journal of Surgical Oncology. Unidade: FMRP
Subjects: HOSPITAIS, NEOPLASIAS OVARIANAS, CIRURGIA, ADENOCARCINOMA, MORTALIDADE, ESTUDOS RETROSPECTIVOS, TAXA DE SOBREVIVÊNCIA, ESTATÍSTICAS DE SAÚDE, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MOTERANI, Vinicius Cesar; TIEZZI, Daniel Guimarães; ANDRADE, Jurandyr Moreira de; REIS, Francisco José Cândido dos. Analysis of the relationship between hospital characteristics and survival in ovarian cancer: A historical cohort. Journal of Surgical Oncology, Hoboken, v. 122, n. 8, p. 1802-1807, 2020. Disponível em: < https://doi.org/10.1002/jso.26186 > DOI: 10.1002/jso.26186.
APA
Moterani, V. C., Tiezzi, D. G., Andrade, J. M. de, & Reis, F. J. C. dos. (2020). Analysis of the relationship between hospital characteristics and survival in ovarian cancer: A historical cohort. Journal of Surgical Oncology, 122( 8), 1802-1807. doi:10.1002/jso.26186
NLM
Moterani VC, Tiezzi DG, Andrade JM de, Reis FJC dos. Analysis of the relationship between hospital characteristics and survival in ovarian cancer: A historical cohort [Internet]. Journal of Surgical Oncology. 2020 ; 122( 8): 1802-1807.Available from: https://doi.org/10.1002/jso.26186
Vancouver
Moterani VC, Tiezzi DG, Andrade JM de, Reis FJC dos. Analysis of the relationship between hospital characteristics and survival in ovarian cancer: A historical cohort [Internet]. Journal of Surgical Oncology. 2020 ; 122( 8): 1802-1807.Available from: https://doi.org/10.1002/jso.26186
Artigo de periodico
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study (2020)
Swain, Sandra M.; Knott, Adam; Restuccia, Eleonora; Benyunes, Mark C.; Cortés, Javier; Andrade, Jurandyr Moreira de ; Miles, David; Kim, Sung Bae; Im, Young-Hyuck; Im, Seock-Ah; Semiglazov, Vladimir; Ciruelos, Eva M.; Schneeweiss, Andreas; Loi, Sherene; Monturus, Estefanía; Clark, Emma
Source: The Lancet Oncology. Unidade: FMRP
Subjects: ANTICORPOS MONOCLONAIS, PROTOCOLOS CLÍNICOS, QUIMIOTERAPIA COMBINADA, ANTINEOPLÁSICOS, NEOPLASIAS MAMÁRIAS, MÉTODO DUPLO-CEGO, METÁSTASE NEOPLÁSICA, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SWAIN, Sandra M.; KNOTT, Adam; RESTUCCIA, Eleonora; et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. The Lancet Oncology, London, v. 21, n. 4, p. 519-530, 2020. Disponível em: < https://doi.org/10.1016/S1470-2045(19)30863-0 > DOI: 10.1016/S1470-2045(19)30863-0.
APA
Swain, S. M., Knott, A., Restuccia, E., Benyunes, M. C., Cortés, J., Andrade, J. M. de, et al. (2020). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. The Lancet Oncology, 21( 4), 519-530. doi:10.1016/S1470-2045(19)30863-0
NLM
Swain SM, Knott A, Restuccia E, Benyunes MC, Cortés J, Andrade JM de, Miles D, Kim SB, Im Y-H, Im S-A, Semiglazov V, Ciruelos EM, Schneeweiss A, Loi S, Monturus E, Clark E. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study [Internet]. The Lancet Oncology. 2020 ; 21( 4): 519-530.Available from: https://doi.org/10.1016/S1470-2045(19)30863-0
Vancouver
Swain SM, Knott A, Restuccia E, Benyunes MC, Cortés J, Andrade JM de, Miles D, Kim SB, Im Y-H, Im S-A, Semiglazov V, Ciruelos EM, Schneeweiss A, Loi S, Monturus E, Clark E. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study [Internet]. The Lancet Oncology. 2020 ; 21( 4): 519-530.Available from: https://doi.org/10.1016/S1470-2045(19)30863-0
Artigo de periodico
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium (2020)
Martins, Filipe Correia; Chow, Christine; Nazeran, Tayyebeh M.; Odunsi, Adekunle; Sousa, Christiani B. de; Tiezzi, Daniel Guimarães ; Andrade, Jurandyr Moreira de ; Reis, Francisco José Candido dos ; Couturier, Dominique-Laurent; Paterson, Anna; Karnezis, Anthony N.
Source: British Journal of Cancer. Unidade: FMRP
Subjects: ADENOCARCINOMA, MORTALIDADE, BIOMARCADORES, NEOPLASIAS OVARIANAS, GENÉTICA, ESTUDOS DE COORTES, ESTUDOS PROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MARTINS, Filipe Correia; CHOW, Christine; NAZERAN, Tayyebeh M.; et al. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, London, v. 123, p. 793-802, 2020. Disponível em: < https://doi.org/10.1038/s41416-020-0900-0 > DOI: 10.1038/s41416-020-0900-0.
APA
Martins, F. C., Chow, C., Nazeran, T. M., Odunsi, A., Sousa, C. B. de, Tiezzi, D. G., et al. (2020). Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 123, 793-802. doi:10.1038/s41416-020-0900-0
NLM
Martins FC, Chow C, Nazeran TM, Odunsi A, Sousa CB de, Tiezzi DG, Andrade JM de, Reis FJC dos, Couturier D-L, Paterson A, Karnezis AN. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium [Internet]. British Journal of Cancer. 2020 ; 123 793-802.Available from: https://doi.org/10.1038/s41416-020-0900-0
Vancouver
Martins FC, Chow C, Nazeran TM, Odunsi A, Sousa CB de, Tiezzi DG, Andrade JM de, Reis FJC dos, Couturier D-L, Paterson A, Karnezis AN. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium [Internet]. British Journal of Cancer. 2020 ; 123 793-802.Available from: https://doi.org/10.1038/s41416-020-0900-0
Artigo de periodico-carta/editorial
Current breast cancer screening scenario in Brazil. [Editorial] (2019)
Tiezzi, Daniel Guimarães ; Orlandini, Leonardo Fleury ; Carrara, Helio Humberto Angotti ; Reis, Francisco José Candido dos ; Andrade, Jurandyr Moreira de
Source: Revista Brasileira de Ginecologia e Obstetrícia. Unidade: FMRP
Subjects: NEOPLASIAS MAMÁRIAS, ESTATÍSTICAS DE SAÚDE, INCIDÊNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TIEZZI, Daniel Guimarães; ORLANDINI, Leonardo Fleury; CARRARA, Helio Humberto Angotti; REIS, Francisco José Candido dos; ANDRADE, Jurandyr Moreira de. Current breast cancer screening scenario in Brazil. [Editorial]. Revista Brasileira de Ginecologia e Obstetrícia[S.l: s.n.], 2019.Disponível em: DOI: 10.1055/s-0039-3399550.
APA
Tiezzi, D. G., Orlandini, L. F., Carrara, H. H. A., Reis, F. J. C. dos, & Andrade, J. M. de. (2019). Current breast cancer screening scenario in Brazil. [Editorial]. Revista Brasileira de Ginecologia e Obstetrícia. São Paulo. doi:10.1055/s-0039-3399550
NLM
Tiezzi DG, Orlandini LF, Carrara HHA, Reis FJC dos, Andrade JM de. Current breast cancer screening scenario in Brazil. [Editorial] [Internet]. Revista Brasileira de Ginecologia e Obstetrícia. 2019 ; 41( 11): 633-635.Available from: https://doi.org/10.1055/s-0039-3399550
Vancouver
Tiezzi DG, Orlandini LF, Carrara HHA, Reis FJC dos, Andrade JM de. Current breast cancer screening scenario in Brazil. [Editorial] [Internet]. Revista Brasileira de Ginecologia e Obstetrícia. 2019 ; 41( 11): 633-635.Available from: https://doi.org/10.1055/s-0039-3399550
Artigo de periodico
Weight gain during systemic oncologic therapy for breast cancer: changes in food intake and physical activity (2019)
Sousa, Marco Aurélio da Silva Ribeiro ; Mastelaro, Isabelle; Peria, Fernanda Maris ; Carrara, Helio Humberto Angotti ; Andrade, Jurandyr Moreira de ; Cunha, Selma Freire de Carvalho da
Source: Revista Brasileira de Cancerologia. Unidade: FMRP
Subjects: NEOPLASIAS MAMÁRIAS, GANHO DE PESO, INGESTÃO, ALIMENTOS, EXERCÍCIO FÍSICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUSA, Marco Aurélio da Silva Ribeiro; MASTELARO, Isabelle; PERIA, Fernanda Maris; et al. Weight gain during systemic oncologic therapy for breast cancer: changes in food intake and physical activity. Revista Brasileira de Cancerologia, Rio de Janeiro, v. 65, n. 2, 2019. Disponível em: < https://doi.org/10.32635/2176-9745.RBC.2019v65n2.360 > DOI: 10.32635/2176-9745.RBC.2019v65n2.360.
APA
Sousa, M. A. da S. R., Mastelaro, I., Peria, F. M., Carrara, H. H. A., Andrade, J. M. de, & Cunha, S. F. de C. da. (2019). Weight gain during systemic oncologic therapy for breast cancer: changes in food intake and physical activity. Revista Brasileira de Cancerologia, 65( 2). doi:10.32635/2176-9745.RBC.2019v65n2.360
NLM
Sousa MA da SR, Mastelaro I, Peria FM, Carrara HHA, Andrade JM de, Cunha SF de C da. Weight gain during systemic oncologic therapy for breast cancer: changes in food intake and physical activity [Internet]. Revista Brasileira de Cancerologia. 2019 ; 65( 2):Available from: https://doi.org/10.32635/2176-9745.RBC.2019v65n2.360
Vancouver
Sousa MA da SR, Mastelaro I, Peria FM, Carrara HHA, Andrade JM de, Cunha SF de C da. Weight gain during systemic oncologic therapy for breast cancer: changes in food intake and physical activity [Internet]. Revista Brasileira de Cancerologia. 2019 ; 65( 2):Available from: https://doi.org/10.32635/2176-9745.RBC.2019v65n2.360
Trabalho de evento-anais periodico
Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients (2019)
Ximenez, João Paulo Bianchi ; Andrade, Jurandyr Moreira de ; Marques, Maria Paula ; Coelho, Eduardo Barbosa ; Suarez-Kurtz, Guilherme ; Lanchote, Vera Lucia
Source: BMC Pharmacology and Toxicology. Conference titles: Latin American Congress of Clinical and Laboratorial Toxicology - ToxiLatin. Unidades: FMRP, FCFRP
Subjects: NEOPLASIAS MAMÁRIAS, RECEPTORES DE DROGA, QUIMIOTERAPIA, ESTRÓGENOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
XIMENEZ, João Paulo Bianchi; ANDRADE, Jurandyr Moreira de; MARQUES, Maria Paula; et al. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. BMC Pharmacology and Toxicology[S.l: s.n.], 2019.Disponível em: DOI: 10.1186/s40360-019-0358-y.
APA
Ximenez, J. P. B., Andrade, J. M. de, Marques, M. P., Coelho, E. B., Suarez-Kurtz, G., & Lanchote, V. L. (2019). Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. BMC Pharmacology and Toxicology. London. doi:10.1186/s40360-019-0358-y
NLM
Ximenez JPB, Andrade JM de, Marques MP, Coelho EB, Suarez-Kurtz G, Lanchote VL. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients [Internet]. BMC Pharmacology and Toxicology. 2019 ; 20 [10] .Available from: https://doi.org/10.1186/s40360-019-0358-y
Vancouver
Ximenez JPB, Andrade JM de, Marques MP, Coelho EB, Suarez-Kurtz G, Lanchote VL. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients [Internet]. BMC Pharmacology and Toxicology. 2019 ; 20 [10] .Available from: https://doi.org/10.1186/s40360-019-0358-y
Artigo de periodico
Prognostic factors for response to chemotherapy in advanced tumors of the uterine cervix: the role of neoangiogenesis (2019)
Kfouri, Cláudio Franco do Amaral; Lombardi, Welington; Romania, Maria Clara Ferreira Nonato; Puls, Matheus Lopes; Ferreira, Rodrigo Amaral Martins; Lombardi, Luciana Borges; Andrade, Jurandyr Moreira de
Source: Revista do Colégio Brasileiro de Cirurgiões. Unidade: FMRP
Subjects: NEOPLASIAS UTERINAS, NEOVASCULARIZAÇÃO PATOLÓGICA, COLO UTERINO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KFOURI, Cláudio Franco do Amaral; LOMBARDI, Welington; ROMANIA, Maria Clara Ferreira Nonato; et al. Prognostic factors for response to chemotherapy in advanced tumors of the uterine cervix: the role of neoangiogenesis. Revista do Colégio Brasileiro de Cirurgiões, Rio de Janeiro, v. 46, n. 1, 2019. Disponível em: < https://doi.org/10.1590/0100-6991e-20192077 > DOI: 10.1590/0100-6991e-20192077.
APA
Kfouri, C. F. do A., Lombardi, W., Romania, M. C. F. N., Puls, M. L., Ferreira, R. A. M., Lombardi, L. B., & Andrade, J. M. de. (2019). Prognostic factors for response to chemotherapy in advanced tumors of the uterine cervix: the role of neoangiogenesis. Revista do Colégio Brasileiro de Cirurgiões, 46( 1). doi:10.1590/0100-6991e-20192077
NLM
Kfouri CF do A, Lombardi W, Romania MCFN, Puls ML, Ferreira RAM, Lombardi LB, Andrade JM de. Prognostic factors for response to chemotherapy in advanced tumors of the uterine cervix: the role of neoangiogenesis [Internet]. Revista do Colégio Brasileiro de Cirurgiões. 2019 ; 46( 1):Available from: https://doi.org/10.1590/0100-6991e-20192077
Vancouver
Kfouri CF do A, Lombardi W, Romania MCFN, Puls ML, Ferreira RAM, Lombardi LB, Andrade JM de. Prognostic factors for response to chemotherapy in advanced tumors of the uterine cervix: the role of neoangiogenesis [Internet]. Revista do Colégio Brasileiro de Cirurgiões. 2019 ; 46( 1):Available from: https://doi.org/10.1590/0100-6991e-20192077
Artigo de periodico
Mammography coverage and tumor stage in the opportunistic screening context (2019)
Magario, Marcos Benini; Poli Netto, Omero Benedicto ; Tiezzi, Daniel Guimarães ; Carrara, Helio Humberto Angotti ; Andrade, Jurandyr Moreira de ; Reis, Francisco José Candido dos
Source: Clinical Breast Cancer. Unidade: FMRP
Subjects: NEOPLASIAS MAMÁRIAS, ESTUDOS ECOLÓGICOS, MAMOGRAFIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MAGARIO, Marcos Benini; POLI NETTO, Omero Benedicto; TIEZZI, Daniel Guimarães; et al. Mammography coverage and tumor stage in the opportunistic screening context. Clinical Breast Cancer, New York, v. 19, n. 6, p. 456-459, 2019. Disponível em: < https://doi.org/10.1016/j.clbc.2019.04.014 > DOI: 10.1016/j.clbc.2019.04.014.
APA
Magario, M. B., Poli Netto, O. B., Tiezzi, D. G., Carrara, H. H. A., Andrade, J. M. de, & Reis, F. J. C. dos. (2019). Mammography coverage and tumor stage in the opportunistic screening context. Clinical Breast Cancer, 19( 6), 456-459. doi:10.1016/j.clbc.2019.04.014
NLM
Magario MB, Poli Netto OB, Tiezzi DG, Carrara HHA, Andrade JM de, Reis FJC dos. Mammography coverage and tumor stage in the opportunistic screening context [Internet]. Clinical Breast Cancer. 2019 ; 19( 6): 456-459.Available from: https://doi.org/10.1016/j.clbc.2019.04.014
Vancouver
Magario MB, Poli Netto OB, Tiezzi DG, Carrara HHA, Andrade JM de, Reis FJC dos. Mammography coverage and tumor stage in the opportunistic screening context [Internet]. Clinical Breast Cancer. 2019 ; 19( 6): 456-459.Available from: https://doi.org/10.1016/j.clbc.2019.04.014
Artigo de periodico
Increased STAT1 expression in high grade serous ovarian cancer is associated with a better outcome (2018)
Josahkian, Juliana A.; Saggioro, Fabiano Pinto; Vidotto, Thiago; Ventura, Henrique Torres; Reis, Francisco José Cândido dos; Sousa, Christiâni Bisinoto de; Tiezzi, Daniel Guimarães; Andrade, Jurandyr Moreira de; Koti, Madhuri; Squire, Jeremy Andrew
Source: International Journal of Gynecological Cancer. Unidades: SVOI, FMRP
Subjects: BIOMARCADORES, ESTUDOS DE COORTES, IMUNOHISTOQUÍMICA, NEOPLASIAS OVARIANAS, FATORES DE RISCO, FATORES DE TRANSCRIÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
JOSAHKIAN, Juliana A.; SAGGIORO, Fabiano Pinto; VIDOTTO, Thiago; et al. Increased STAT1 expression in high grade serous ovarian cancer is associated with a better outcome. International Journal of Gynecological Cancer, London, v. 28, n. 3, p. 459-465, 2018. Disponível em: < http://dx.doi.org/10.1097/igc.0000000000001193 > DOI: 10.1097/igc.0000000000001193.
APA
Josahkian, J. A., Saggioro, F. P., Vidotto, T., Ventura, H. T., Reis, F. J. C. dos, Sousa, C. B. de, et al. (2018). Increased STAT1 expression in high grade serous ovarian cancer is associated with a better outcome. International Journal of Gynecological Cancer, 28( 3), 459-465. doi:10.1097/igc.0000000000001193
NLM
Josahkian JA, Saggioro FP, Vidotto T, Ventura HT, Reis FJC dos, Sousa CB de, Tiezzi DG, Andrade JM de, Koti M, Squire JA. Increased STAT1 expression in high grade serous ovarian cancer is associated with a better outcome [Internet]. International Journal of Gynecological Cancer. 2018 ; 28( 3): 459-465.Available from: http://dx.doi.org/10.1097/igc.0000000000001193
Vancouver
Josahkian JA, Saggioro FP, Vidotto T, Ventura HT, Reis FJC dos, Sousa CB de, Tiezzi DG, Andrade JM de, Koti M, Squire JA. Increased STAT1 expression in high grade serous ovarian cancer is associated with a better outcome [Internet]. International Journal of Gynecological Cancer. 2018 ; 28( 3): 459-465.Available from: http://dx.doi.org/10.1097/igc.0000000000001193
Artigo de periodico
Identification of a subtype of poorly differentiated invasive ductal carcinoma of the breast based on vimentin and E-cadherin expression (2018)
Orlandini, Leonardo Fleury ; Reis, Francisco José Candido dos ; Silveira, Willian Abraham da; Tiezzi, Marcelo Guimarães; Andrade, Jurandyr Moreira de ; Ribeiro-Silva, Alfredo ; Deaton, Ryan; Bosland, Maarten; Tiezzi, Daniel Guimarães
Source: Revista Brasileira de Ginecologia e Obstetrícia. Unidade: FMRP
Subjects: NEOPLASIAS MAMÁRIAS, VIMENTINA, EPITÉLIO, MARCADOR MOLECULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ORLANDINI, Leonardo Fleury; REIS, Francisco José Candido dos; SILVEIRA, Willian Abraham da; et al. Identification of a subtype of poorly differentiated invasive ductal carcinoma of the breast based on vimentin and E-cadherin expression. Revista Brasileira de Ginecologia e Obstetrícia, Rio de Janeiro, v. 40, n. 12, p. 779-786, 2018. Disponível em: < http://dx.doi.org/10.1055/s-0038-1673700 > DOI: 10.1055/s-0038-1673700.
APA
Orlandini, L. F., Reis, F. J. C. dos, Silveira, W. A. da, Tiezzi, M. G., Andrade, J. M. de, Ribeiro-Silva, A., et al. (2018). Identification of a subtype of poorly differentiated invasive ductal carcinoma of the breast based on vimentin and E-cadherin expression. Revista Brasileira de Ginecologia e Obstetrícia, 40( 12), 779-786. doi:10.1055/s-0038-1673700
NLM
Orlandini LF, Reis FJC dos, Silveira WA da, Tiezzi MG, Andrade JM de, Ribeiro-Silva A, Deaton R, Bosland M, Tiezzi DG. Identification of a subtype of poorly differentiated invasive ductal carcinoma of the breast based on vimentin and E-cadherin expression [Internet]. Revista Brasileira de Ginecologia e Obstetrícia. 2018 ; 40( 12): 779-786.Available from: http://dx.doi.org/10.1055/s-0038-1673700
Vancouver
Orlandini LF, Reis FJC dos, Silveira WA da, Tiezzi MG, Andrade JM de, Ribeiro-Silva A, Deaton R, Bosland M, Tiezzi DG. Identification of a subtype of poorly differentiated invasive ductal carcinoma of the breast based on vimentin and E-cadherin expression [Internet]. Revista Brasileira de Ginecologia e Obstetrícia. 2018 ; 40( 12): 779-786.Available from: http://dx.doi.org/10.1055/s-0038-1673700
Artigo de periodico
Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab (2018)
Pimentel, Franklin Fernandes; Morgan, Gilberto; Tiezzi, Daniel Guimarães; Andrade, Jurandyr Moreira de
Source: Pharmaceutical Medicine. Unidade: FMRP
Subjects: NEOPLASIAS MAMÁRIAS, TERAPIA COMBINADA, QUIMIOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIMENTEL, Franklin Fernandes; MORGAN, Gilberto; TIEZZI, Daniel Guimarães; ANDRADE, Jurandyr Moreira de. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab. Pharmaceutical Medicine, Cham, v. 32, n. 5, p. 319-325, 2018. Disponível em: < http://dx.doi.org/10.1007/s40290-018-0247-5 > DOI: 10.1007/s40290-018-0247-5.
APA
Pimentel, F. F., Morgan, G., Tiezzi, D. G., & Andrade, J. M. de. (2018). Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab. Pharmaceutical Medicine, 32( 5), 319-325. doi:10.1007/s40290-018-0247-5
NLM
Pimentel FF, Morgan G, Tiezzi DG, Andrade JM de. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab [Internet]. Pharmaceutical Medicine. 2018 ; 32( 5): 319-325.Available from: http://dx.doi.org/10.1007/s40290-018-0247-5
Vancouver
Pimentel FF, Morgan G, Tiezzi DG, Andrade JM de. Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab [Internet]. Pharmaceutical Medicine. 2018 ; 32( 5): 319-325.Available from: http://dx.doi.org/10.1007/s40290-018-0247-5
Artigo de periodico
Integrated genomic and molecular characterization of cervical cancer (2017)
Tiezzi, Daniel Guimarães; Andrade, Jurandyr Moreira de; Noushmehr, Houtan; Carlotti Júnior, Carlos Gilberto; Tirapelli, Daniela Pretti da Cunha
Source: Nature. Unidade: FMRP
Subjects: ADENOCARCINOMA, ANTÍGENOS, HPV, PROTEÍNAS QUINASES, PROTEÍNAS PROTO-ONCOGÊNICAS, NEOPLASIAS UTERINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TIEZZI, Daniel Guimarães; ANDRADE, Jurandyr Moreira de; NOUSHMEHR, Houtan; CARLOTTI JÚNIOR, Carlos Gilberto; TIRAPELLI, Daniela Pretti da Cunha. Integrated genomic and molecular characterization of cervical cancer. Nature, London, v. 543, n. 7645, p. 378-384, 2017. Disponível em: < http://dx.doi.org/10.1038/nature21386 > DOI: 10.1038/nature21386.
APA
Tiezzi, D. G., Andrade, J. M. de, Noushmehr, H., Carlotti Júnior, C. G., & Tirapelli, D. P. da C. (2017). Integrated genomic and molecular characterization of cervical cancer. Nature, 543( 7645), 378-384. doi:10.1038/nature21386
NLM
Tiezzi DG, Andrade JM de, Noushmehr H, Carlotti Júnior CG, Tirapelli DP da C. Integrated genomic and molecular characterization of cervical cancer [Internet]. Nature. 2017 ; 543( 7645): 378-384.Available from: http://dx.doi.org/10.1038/nature21386
Vancouver
Tiezzi DG, Andrade JM de, Noushmehr H, Carlotti Júnior CG, Tirapelli DP da C. Integrated genomic and molecular characterization of cervical cancer [Internet]. Nature. 2017 ; 543( 7645): 378-384.Available from: http://dx.doi.org/10.1038/nature21386
Artigo de periodico
Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer (2017)
Goode, Ellen L.; Sousa, Christiâni Bisinoto de; Tiezzi, Daniel Guimarães; Andrade, Jurandyr Moreira de; Reis, Francisco José Cândido dos
Source: JAMA Oncology. Unidade: FMRP
Subjects: NEOPLASIAS OVARIANAS, CITOTOXICIDADE IMUNOLÓGICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GOODE, Ellen L.; SOUSA, Christiâni Bisinoto de; TIEZZI, Daniel Guimarães; ANDRADE, Jurandyr Moreira de; REIS, Francisco José Cândido dos. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncology, Chicago, v. 3, n. 12, 2017. Disponível em: < http://dx.doi.org/10.1001/jamaoncol.2017.3290 > DOI: 10.1001/jamaoncol.2017.3290.
APA
Goode, E. L., Sousa, C. B. de, Tiezzi, D. G., Andrade, J. M. de, & Reis, F. J. C. dos. (2017). Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncology, 3( 12). doi:10.1001/jamaoncol.2017.3290
NLM
Goode EL, Sousa CB de, Tiezzi DG, Andrade JM de, Reis FJC dos. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer [Internet]. JAMA Oncology. 2017 ; 3( 12):Available from: http://dx.doi.org/10.1001/jamaoncol.2017.3290
Vancouver
Goode EL, Sousa CB de, Tiezzi DG, Andrade JM de, Reis FJC dos. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer [Internet]. JAMA Oncology. 2017 ; 3( 12):Available from: http://dx.doi.org/10.1001/jamaoncol.2017.3290
Artigo de periodico
Quality of life in women with breast cancer treated with or without chemotherapy (2017)
Tiezzi, Maria Fernanda Barbirato da Mata; Andrade, Jurandyr Moreira de; Romão, Adriana Peterson Mariano Salata; Tiezzi, Daniel Guimarães; Lerri, Maria Rita; Carrara, Helio Humberto Angotti; Lara, Lúcia da Silva
Source: Cancer Nursing. Unidade: FMRP
Subjects: QUALIDADE DE VIDA, NEOPLASIAS MAMÁRIAS, QUIMIOTERAPIA, RADIOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TIEZZI, Maria Fernanda Barbirato da Mata; ANDRADE, Jurandyr Moreira de; ROMÃO, Adriana Peterson Mariano Salata; et al. Quality of life in women with breast cancer treated with or without chemotherapy. Cancer Nursing, Philadelphia, v. 40, n. 2, p. 108-116, 2017. Disponível em: < http://dx.doi.org/10.1097/NCC.0000000000000370 > DOI: 10.1097/NCC.0000000000000370.
APA
Tiezzi, M. F. B. da M., Andrade, J. M. de, Romão, A. P. M. S., Tiezzi, D. G., Lerri, M. R., Carrara, H. H. A., & Lara, L. da S. (2017). Quality of life in women with breast cancer treated with or without chemotherapy. Cancer Nursing, 40( 2), 108-116. doi:10.1097/NCC.0000000000000370
NLM
Tiezzi MFB da M, Andrade JM de, Romão APMS, Tiezzi DG, Lerri MR, Carrara HHA, Lara L da S. Quality of life in women with breast cancer treated with or without chemotherapy [Internet]. Cancer Nursing. 2017 ;40( 2): 108-116.Available from: http://dx.doi.org/10.1097/NCC.0000000000000370
Vancouver
Tiezzi MFB da M, Andrade JM de, Romão APMS, Tiezzi DG, Lerri MR, Carrara HHA, Lara L da S. Quality of life in women with breast cancer treated with or without chemotherapy [Internet]. Cancer Nursing. 2017 ;40( 2): 108-116.Available from: http://dx.doi.org/10.1097/NCC.0000000000000370
Artigo de periodico
Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors (2017)
Buzatto, I. P. C.; Ribeiro-Silva, Alfredo; Andrade, Jurandyr Moreira de; Carrara, Helio Humberto Angotti; Tiezzi, Daniel Guimarães
Source: Brazilian Journal of Medical and Biological Research. Unidade: FMRP
Subjects: NEOPLASIAS MAMÁRIAS, QUIMIOTERAPIA ADJUVANTE, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BUZATTO, I. P. C.; RIBEIRO-SILVA, Alfredo; ANDRADE, Jurandyr Moreira de; CARRARA, Helio Humberto Angotti; TIEZZI, Daniel Guimarães. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors. Brazilian Journal of Medical and Biological Research, Ribeirão Preto, v. 50, n. 2, 2017. Disponível em: < http://dx.doi.org/10.1590/1414-431x20165674 > DOI: 10.1590/1414-431x20165674.
APA
Buzatto, I. P. C., Ribeiro-Silva, A., Andrade, J. M. de, Carrara, H. H. A., & Tiezzi, D. G. (2017). Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors. Brazilian Journal of Medical and Biological Research, 50( 2). doi:10.1590/1414-431x20165674
NLM
Buzatto IPC, Ribeiro-Silva A, Andrade JM de, Carrara HHA, Tiezzi DG. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors [Internet]. Brazilian Journal of Medical and Biological Research. 2017 ; 50( 2):Available from: http://dx.doi.org/10.1590/1414-431x20165674
Vancouver
Buzatto IPC, Ribeiro-Silva A, Andrade JM de, Carrara HHA, Tiezzi DG. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors [Internet]. Brazilian Journal of Medical and Biological Research. 2017 ; 50( 2):Available from: http://dx.doi.org/10.1590/1414-431x20165674
Artigo de periodico
Transcription Factor Networks derived from Breast Cancer Stem Cells control the immune response in the Basal subtype (2017)
Silveira, W. A. da; Palma, P. V. B.; Sicchieri, R. D.; Villacis, R. A. R.; Mandarano, L. R. M.; Oliveira, T. M. G.; Antonio, H. M. R.; Andrade, Jurandyr Moreira de; Muglia, Valdair Francisco; Rogatto, S. R.; Theillet, C.; du Manoir, S.; Tiezzi, Daniel Guimarães
Source: Scientific Reports. Unidade: FMRP
Subjects: NEOPLASIAS MAMÁRIAS, CÉLULAS-TRONCO, FATORES DE TRANSCRIÇÃO, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVEIRA, W. A. da; PALMA, P. V. B.; SICCHIERI, R. D.; et al. Transcription Factor Networks derived from Breast Cancer Stem Cells control the immune response in the Basal subtype. Scientific Reports, London, v. 7, 2017. Disponível em: < http://dx.doi.org/10.1038/s41598-017-02761-6 > DOI: 10.1038/s41598-017-02761-6.
APA
Silveira, W. A. da, Palma, P. V. B., Sicchieri, R. D., Villacis, R. A. R., Mandarano, L. R. M., Oliveira, T. M. G., et al. (2017). Transcription Factor Networks derived from Breast Cancer Stem Cells control the immune response in the Basal subtype. Scientific Reports, 7. doi:10.1038/s41598-017-02761-6
NLM
Silveira WA da, Palma PVB, Sicchieri RD, Villacis RAR, Mandarano LRM, Oliveira TMG, Antonio HMR, Andrade JM de, Muglia VF, Rogatto SR, Theillet C, du Manoir S, Tiezzi DG. Transcription Factor Networks derived from Breast Cancer Stem Cells control the immune response in the Basal subtype [Internet]. Scientific Reports. 2017 ;7Available from: http://dx.doi.org/10.1038/s41598-017-02761-6
Vancouver
Silveira WA da, Palma PVB, Sicchieri RD, Villacis RAR, Mandarano LRM, Oliveira TMG, Antonio HMR, Andrade JM de, Muglia VF, Rogatto SR, Theillet C, du Manoir S, Tiezzi DG. Transcription Factor Networks derived from Breast Cancer Stem Cells control the immune response in the Basal subtype [Internet]. Scientific Reports. 2017 ;7Available from: http://dx.doi.org/10.1038/s41598-017-02761-6
Artigo de periodico
Trastuzumab use during pregnancy: long-term survival after locally advanced breast cancer and long-term infant follow-up (2016)
Andrade, Jurandyr Moreira de; Brito, Luiz G. O.; Moisés, Elaine Christine Dantas; Amorim, Andréa C.; Rapatoni, Liane; Carrara, Helio Humberto Angotti; Tiezzi, Daniel Guimarães
Source: Anti-Cancer Drugs. Unidade: FMRP
Subjects: ANTINEOPLÁSICOS, NEOPLASIAS MAMÁRIAS, QUIMIOTERAPIA ADJUVANTE, COMPLICAÇÕES NA GRAVIDEZ
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ANDRADE, Jurandyr Moreira de; BRITO, Luiz G. O.; MOISÉS, Elaine Christine Dantas; et al. Trastuzumab use during pregnancy: long-term survival after locally advanced breast cancer and long-term infant follow-up. Anti-Cancer Drugs, Philadelphia, v. 27, n. 4, p. 369-372, 2016. Disponível em: < http://dx.doi.org/10.1097/CAD.0000000000000344 > DOI: 10.1097/CAD.0000000000000344.
APA
Andrade, J. M. de, Brito, L. G. O., Moisés, E. C. D., Amorim, A. C., Rapatoni, L., Carrara, H. H. A., & Tiezzi, D. G. (2016). Trastuzumab use during pregnancy: long-term survival after locally advanced breast cancer and long-term infant follow-up. Anti-Cancer Drugs, 27( 4), 369-372. doi:10.1097/CAD.0000000000000344
NLM
Andrade JM de, Brito LGO, Moisés ECD, Amorim AC, Rapatoni L, Carrara HHA, Tiezzi DG. Trastuzumab use during pregnancy: long-term survival after locally advanced breast cancer and long-term infant follow-up [Internet]. Anti-Cancer Drugs. 2016 ; 27( 4): 369-372.Available from: http://dx.doi.org/10.1097/CAD.0000000000000344
Vancouver
Andrade JM de, Brito LGO, Moisés ECD, Amorim AC, Rapatoni L, Carrara HHA, Tiezzi DG. Trastuzumab use during pregnancy: long-term survival after locally advanced breast cancer and long-term infant follow-up [Internet]. Anti-Cancer Drugs. 2016 ; 27( 4): 369-372.Available from: http://dx.doi.org/10.1097/CAD.0000000000000344
Trabalho de evento-resumo periodico
Germ cells and mammary gland transcritome comparison generate a powerful gene expression profile that predicts breast cancer survival (2015)
Tiezzi, Daniel Guimarães; Noushmehr, Houtan; Silveira, W. A; Sabedot, T. S; Andrade, Jurandyr Moreira de
Source: Annals of Oncology. Conference titles: IMPAKT Breast Cancer Conference. Unidade: FMRP
Subjects: NEOPLASIAS MAMÁRIAS (GENÉTICA), EXPRESSÃO GÊNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TIEZZI, Daniel Guimarães; NOUSHMEHR, Houtan; SILVEIRA, W. A; SABEDOT, T. S; ANDRADE, Jurandyr Moreira de. Germ cells and mammary gland transcritome comparison generate a powerful gene expression profile that predicts breast cancer survival. Annals of Oncology[S.l: s.n.], 2015.Disponível em: DOI: 10.1093/annonc/mdv116.6.
APA
Tiezzi, D. G., Noushmehr, H., Silveira, W. A., Sabedot, T. S., & Andrade, J. M. de. (2015). Germ cells and mammary gland transcritome comparison generate a powerful gene expression profile that predicts breast cancer survival. Annals of Oncology. Oxford. doi:10.1093/annonc/mdv116.6
NLM
Tiezzi DG, Noushmehr H, Silveira WA, Sabedot TS, Andrade JM de. Germ cells and mammary gland transcritome comparison generate a powerful gene expression profile that predicts breast cancer survival [Internet]. Annals of Oncology. 2015 ; 26( 8):Available from: http://annonc.oxfordjournals.org/content/26/suppl_3/iii11.3.full.pdf+html?sid=6c8beebc-2a9c-48dd-83d4-b47db4349b87
Vancouver
Tiezzi DG, Noushmehr H, Silveira WA, Sabedot TS, Andrade JM de. Germ cells and mammary gland transcritome comparison generate a powerful gene expression profile that predicts breast cancer survival [Internet]. Annals of Oncology. 2015 ; 26( 8):Available from: http://annonc.oxfordjournals.org/content/26/suppl_3/iii11.3.full.pdf+html?sid=6c8beebc-2a9c-48dd-83d4-b47db4349b87
Artigo de periodico
IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment (2015)
Benevides, Luciana; Fonseca, Denise Morais da; Donate, Paula Barbim; Tiezzi, Daniel Guimarães; Carvalho, Daniel D. de; Andrade, Jurandyr Moreira de; Martins, Gislaine Aparecida; Silva, João Santana da
Source: Cancer Research. Unidade: FMRP
Subjects: NEOPLASIAS MAMÁRIAS, CARCINOMA DE DUCTOS INFILTRANTE, CITOCINAS, SOBREVIVÊNCIA LIVRE DE DOENÇA, REGULAÇÃO GÊNICA, EXPRESSÃO GÊNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BENEVIDES, Luciana; FONSECA, Denise Morais da; DONATE, Paula Barbim; et al. IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment. Cancer Research, Baltimore, v. 75, n. 8, p. 3788-3799, 2015. Disponível em: < http://dx.doi.org/10.1158/0008-5472.CAN-15-0054 > DOI: 10.1158/0008-5472.CAN-15-0054.
APA
Benevides, L., Fonseca, D. M. da, Donate, P. B., Tiezzi, D. G., Carvalho, D. D. de, Andrade, J. M. de, et al. (2015). IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment. Cancer Research, 75( 8), 3788-3799. doi:10.1158/0008-5472.CAN-15-0054
NLM
Benevides L, Fonseca DM da, Donate PB, Tiezzi DG, Carvalho DD de, Andrade JM de, Martins GA, Silva JS da. IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment [Internet]. Cancer Research. 2015 ; 75( 8): 3788-3799.Available from: http://dx.doi.org/10.1158/0008-5472.CAN-15-0054
Vancouver
Benevides L, Fonseca DM da, Donate PB, Tiezzi DG, Carvalho DD de, Andrade JM de, Martins GA, Silva JS da. IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment [Internet]. Cancer Research. 2015 ; 75( 8): 3788-3799.Available from: http://dx.doi.org/10.1158/0008-5472.CAN-15-0054

USP Schools

ReP

Filtros

Document Types

USP Schools

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Publisher

Conference titles

Countries/Territories

Funding Agencies

Non normalized affiliation

Countries of institutions of collaboration

Keywords